TY - JOUR
T1 - A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
AU - Sun, Weina
AU - Liu, Yonghong
AU - Amanat, Fatima
AU - González-Domínguez, Irene
AU - McCroskery, Stephen
AU - Slamanig, Stefan
AU - Coughlan, Lynda
AU - Rosado, Victoria
AU - Lemus, Nicholas
AU - Jangra, Sonia
AU - Rathnasinghe, Raveen
AU - Schotsaert, Michael
AU - Martinez, Jose L.
AU - Sano, Kaori
AU - Mena, Ignacio
AU - Innis, Bruce L.
AU - Wirachwong, Ponthip
AU - Thai, Duong Huu
AU - Oliveira, Ricardo Das Neves
AU - Scharf, Rami
AU - Hjorth, Richard
AU - Raghunandan, Rama
AU - Krammer, Florian
AU - García-Sastre, Adolfo
AU - Palese, Peter
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.
AB - Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation of vaccines is necessary to limit the global impact of the COVID-19 pandemic and the emergence of additional variants of concern. We have developed a COVID-19 vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show that the NDV vector expressing an optimized spike antigen (NDV-HXP-S) is a versatile vaccine inducing protective antibody responses. NDV-HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine. We show that NDV-HXP-S GMP-produced in Vietnam, Thailand and Brazil is effective in the hamster model. Furthermore, we show that intramuscular vaccination with NDV-HXP-S reduces replication of tested variants of concerns in mice. The immunity conferred by NDV-HXP-S effectively counteracts SARS-CoV-2 infection in mice and hamsters.
UR - https://www.scopus.com/pages/publications/85117931225
U2 - 10.1038/s41467-021-26499-y
DO - 10.1038/s41467-021-26499-y
M3 - Article
C2 - 34707161
AN - SCOPUS:85117931225
SN - 2041-1723
VL - 12
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 6197
ER -